SCIEX

Webinar Date/Time: Tue, Dec 9, 2025 2:00 PM EST

Throughout drug development, it is important to characterize and quantify pharmaceutical compounds and any associated metabolites to ensure proper drug safety and efficacy. LC-MS/MS techniques are predominantly used for such analyses because they provide a comprehensive outlook and can offer a sensitive and selective approach for the quantification of compounds. However, limited deep fragment coverage and sensitivity challenge the confident identification and quantification of metabolites and drug products. Here, alternative fragmentation paired with a highly sensitive QTOF system was employed for comprehensive data collection to properly identify metabolites and quantify complex peptide therapeutics.

• The identification of drug metabolites is a critical step in drug development due to their impact on drug efficacy and safety. LC-MS platforms provide good selectivity and sensitivity making it the preferred technique for metabolite identification. Here, metabolite identification was performed using unique fragments from EAD and CID spectra. Fragment information from EAD and CID spectra were processed in a single result file to achieve confident structure assignment of and localization of metabolites.

Learn about the end-to-end solution for metabolite identification from method development to analysis.

Discover how the targeted metabolomics screening workflow employing integrated SCIEX OS Software with the X500 QTOF System can benefit your lab.

This technical note describes the identification of pioglitazone phase 1 metabolites from a hepatocyte incubation using comprehensive spectral data from an orthogonal fragmentation technique. More informative MS/MS spectra provided by EAD aided in the software-based identification of phase 1 metabolites to support drug metabolism studies.

This technical note demonstrates the comprehensive characterization and confident identification of glucuronide metabolites from hepatocyte incubations of midazolam.

Nitrosamine contamination in pharmaceuticals has become a major regulatory concern due to their potent carcinogenicity, requiring ultra-trace-level detection to ensure patient safety. Advanced LC-MS/MS workflows provide the necessary sensitivity, selectivity, and robustness to accurately quantify nitrosamine drug substance-related impurities (NDSRIs), even within complex pharmaceutical matrices. Case studies with betahistine, orphenadrine, and chloropyramine demonstrate how streamlined LC-MS/MS strategies can reliably detect and confirm nitrosamine impurities well below regulatory thresholds.

PROTACs are protein degraders that harness the cell’s disposal machinery to remove specific targets. Now advancing into clinical trials, they show high potency at nanomolar levels. To support safe and effective drug development, sensitive and selective assays are essential for reliable detection and quantification.

Join us to see how SCIEX OS software helps you meet regulatory requirements with confidence. This webinar highlights new features and tools that strengthen data integrity, improve quality control, and save valuable lab time.

This infographic explores the benefits of Acoustic Ejection Mass Spectrometry (AEMS)- based workflows for efficient small and large molecule screening.

Webinar Date/Time: Thu, Oct 2, 2025 11:00 AM EDT

We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created this solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options. This guide covers bio/pharmaceutical quantitative assays from discovery to QA/QC, for large and small molecules. Happy reading!

As a leader responsible for metabolite identification in your organization, what keeps you awake at night? SCIEX can give you peace of mind by helping you . . .

Webinar Date/Time: Thu, Jul 10, 2025 11:00 AM EDT

Webinar Date/Time: Thu, Jun 26, 2025 11:00 AM EDT

Webinar Date/Time: Tue, Jun 17, 2025 11:00 AM EDT

As a leader responsible for metabolite identification in your organization, what keeps you awake at night? SCIEX can give you peace of mind by helping you . . .

Here we discuss a software-assisted drug metabolite identification and characterization workflow. The approach allows scientists to have increased confidence in the process.

The dream state If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery. At SCIEX, we believe that metabolite identification using the ZenoTOF 7600 system gets close to this dream state.

Glycan analysis provides key information on critical quality attributes that could affect stability, safety and efficacy of a protein therapeutic. Specific needs for understanding the glycosylation profiles change throughout the drug development process, but the requirement for high-resolution glycan information remains the same and is essential to help ensure product quality.

Webinar Date/Time: Thu, Nov 7, 2024 11:00 AM EDT

Webinar Date/Time: Mon, Aug 12, 2024 9:00 AM EDT

Webinar Date/Time: Wed, Jul 24, 2024 12:00 PM EDT

Charge heterogeneity is present in most biopharmaceutical protein products. During the manufacturing process, charge heterogeneity of the protein therapeutics can occur due to enzymatic cleavage and chemical post-translational modifications (PTM). For therapeutics like ADCs, not only the antibody contributes to the heterogeneity but also the linker and payload, which add even more complexity to the charge variant profiles. Characterizing the charge heterogeneity of ADCs is essential for critical quality attribute (CQA) assessment to ensure drug safety, efficacy, and potency.

Clinical trials can be helpful indicators of where the life sciences industry is headed. Dean Erhardt, BBA, MBA, President & CEO of D2 Solutions, offers his insights regarding the direction of the market and potential growth areas.

Webinar Date/Time: Tue, May 21, 2024 11:00 AM EDT

Webinar Date/Time: Thu, Apr 4, 2024 10:00 AM EDT